Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166.
Article
PubMed
Google Scholar
Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, Chen H, Jin J, Peng C, Li H, Shen B: Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res. 2013, 354 (3): 891-896. 10.1007/s00441-013-1711-x.
Article
CAS
PubMed
Google Scholar
Tremblay A, Michaud G: Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006, 129 (2): 362-368. 10.1378/chest.129.2.362.
Article
PubMed
Google Scholar
Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 1997, 3 (1): 47-50.
CAS
PubMed
Google Scholar
Heffner JE, Klein JS: Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008, 83 (2): 235-250. 10.1016/S0025-6196(11)60848-3.
Article
PubMed
Google Scholar
Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S: Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21–1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007, 21 (6): 398-405. 10.1002/jcla.20208.
Article
CAS
PubMed
Google Scholar
Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB: Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008, 63 (1): 35-41. 10.1136/thx.2007.077958.
Article
PubMed
Google Scholar
Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986, 83 (23): 8819-8823. 10.1073/pnas.83.23.8819.
Article
CAS
PubMed
PubMed Central
Google Scholar
Heinegard D, Hultenby K, Oldberg A, Reinholt F, Wendel M: Macromolecules in bone matrix. Connect Tissue Res. 1989, 21 (1–4): 3-11. discussion 12–14
Article
CAS
PubMed
Google Scholar
Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest. 1995, 72 (1): 55-63.
CAS
PubMed
Google Scholar
Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006, 16 (2): 79-87. 10.1016/j.tcb.2005.12.005.
Article
CAS
PubMed
Google Scholar
Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC: Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011, 15 (9): 1113-1126. 10.1517/14728222.2011.594438.
Article
CAS
PubMed
Google Scholar
Rittling SR, Chen Y, Feng F, Wu Y: Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem. 2002, 277 (11): 9175-9182. 10.1074/jbc.M109028200.
Article
CAS
PubMed
Google Scholar
Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998, 79 (2): 127-132. 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V.
Article
CAS
PubMed
Google Scholar
Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001, 7 (12): 4060-4066.
CAS
PubMed
Google Scholar
Chuang CY, Chang H, Lin P, Sun SJ, Chen PH, Lin YY, Sheu GT, Ko JL, Hsu SL, Chang JT: Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene. 2012, 492 (1): 262-269. 10.1016/j.gene.2011.10.019.
Article
CAS
PubMed
Google Scholar
Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, Iwase A, Takahashi K: Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer. 2009, 63 (3): 368-374. 10.1016/j.lungcan.2008.06.020.
Article
PubMed
Google Scholar
Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, Papiris SA, Roussos C, Kalomenidis I: Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene. 2013, 32 (4): 528-535. 10.1038/onc.2012.57.
Article
CAS
PubMed
Google Scholar
Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011, 147 (2): 275-292. 10.1016/j.cell.2011.09.024.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005, 11 (13): 4646-4652. 10.1158/1078-0432.CCR-04-2013.
Article
CAS
PubMed
Google Scholar
Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 2004, 10 (5): 1588-1596. 10.1158/1078-0432.CCR-0565-3.
Article
CAS
PubMed
Google Scholar
Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005, 11 (18): 6459-6465. 10.1158/1078-0432.CCR-05-0541.
Article
CAS
PubMed
Google Scholar
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR: Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008, 26 (29): 4771-4776. 10.1200/JCO.2008.17.0662.
Article
CAS
PubMed
PubMed Central
Google Scholar
Elsammak MM, Morsi TS, Khamis HI, Ragab MS, Zaki MA, Abdel-Hadi M, Hassan HA: Osteopontin and C-reactive protein in Egyptian patients affected with tuberculous and malignant pleural effusion. Ann Clin Biochem. 2007, 44 (Pt 3): 264-272.
Article
Google Scholar
Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I: Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology. 2009, 14 (5): 716-722. 10.1111/j.1440-1843.2009.01536.x.
Article
PubMed
Google Scholar
O’Regan A: The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003, 14 (6): 479-488. 10.1016/S1359-6101(03)00055-8.
Article
PubMed
Google Scholar
Inomata S, Shijubo N, Kon S, Maeda M, Yamada G, Sato N, Abe S, Uede T: Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine. 2005, 30 (4): 203-211. 10.1016/j.cyto.2005.01.014.
Article
CAS
PubMed
Google Scholar